Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States

BACKGROUND: Immune checkpoint inhibitors (ICIs) can cause life-threatening cardiovascular adverse events (CVAEs) that may not be attributed to therapy. The outcomes of clinical trials may underestimate treatment-related adverse events due to restrictive eligibility, limited sample size, and failure...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, P., Gutierrez Bugarin, J., Guha, A., Jain, C., Patil, N., Shen, T., Stanevich, I., Nikore, V., Margolin, K., Ernstoff, M., Velcheti, V., Barnholtz-Sloan, J., Dowlati, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403739/
https://www.ncbi.nlm.nih.gov/pubmed/34461483
http://dx.doi.org/10.1016/j.esmoop.2021.100252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403739/
https://www.ncbi.nlm.nih.gov/pubmed/34461483
http://dx.doi.org/10.1016/j.esmoop.2021.100252

Ejemplares similares